Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: October 23, 2018
Pages: 56
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: G9AB7D6B6A2EN
Leaflet:

Download PDF Leaflet

Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Genocea Biosciences Inc (Genocea), formerly GenoceaInc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas technology uses a cellular assay to comprehensively re-create a patient’s actual immune response to cancer. The company’s Gen-009 cancer vaccines are being designed to educate T cells to recognize and attack specific targets and thereby kill cancers. It offers pre-clinical and clinical investigational immunotherapies. The compnay’s partnership program includes antigen discovery, immune responsw profiling, Gen-003 for general herpes and other disease programs.Genocea is headquartered in Cambridge, Massachusetts, the US.

Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners
Genocea Biosciences Raises US$0.4 Million In Venture Financing
Genocea Biosciences Raises US$30 Million In Series C Financing
Partnerships
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma
Genocea Biosciences Enters into Agreement with US Oncology Research
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School
Licensing Agreements
Genocea Biosciences Enters into Licensing Agreement with Oncovir
Equity Offering
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares
Genocea Biosciences Raises USD50 Million in Public Offering of Shares
Genocea Biosciences Raises USD52 Million in Public Offering of Shares
Genocea Biosciences Raises USD2 Million in Private Placement of Shares
Genocea Biosciences Withdraws Public Offering of Shares
Genocea Biosciences Completes IPO For US$66 Million
Genocea Biosciences Inc - Key Competitors
Genocea Biosciences Inc - Key Employees
Genocea Biosciences Inc - Locations And Subsidiaries
Head Office
Recent Developments
Financial Announcements
Aug 02, 2018: Genocea reports second quarter 2018 financial and operating results
May 10, 2018: Genocea Reports First Quarter 2018 Financial and Operating Results
Feb 15, 2018: Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
Nov 02, 2017: Genocea Reports Third Quarter 2017 Financial Results
Aug 09, 2017: Genocea Biosciences Reports Second Quarter 2017 Financial Results
May 04, 2017: Genocea Reports First Quarter 2017 Financial Results
May 04, 2017: Genocea Biosciences Q1 net loss increases
Feb 16, 2017: Genocea Reports Fourth Quarter and Year-End 2016 Financial Results
Corporate Communications
Mar 12, 2018: Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing
Feb 12, 2018: Genocea Biosciences Names Ali Behbahani, M.D., As Board Director
Mar 06, 2017: Howard Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors
Product News
09/25/2017: Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccine GEN-009
04/18/2018: Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods
04/09/2018: Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines
Product Approvals
Apr 30, 2018: Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Genocea Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners
Genocea Biosciences Raises US$0.4 Million In Venture Financing
Genocea Biosciences Raises US$30 Million In Series C Financing
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma
Genocea Biosciences Enters into Agreement with US Oncology Research
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School
Genocea Biosciences Enters into Licensing Agreement with Oncovir
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares
Genocea Biosciences Raises USD50 Million in Public Offering of Shares
Genocea Biosciences Raises USD52 Million in Public Offering of Shares
Genocea Biosciences Raises USD2 Million in Private Placement of Shares
Genocea Biosciences Withdraws Public Offering of Shares
Genocea Biosciences Completes IPO For US$66 Million
Genocea Biosciences Inc, Key Competitors
Genocea Biosciences Inc, Key Employees

LIST OF FIGURES

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Skip to top


Ask Your Question

Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: